ALX Oncology Holdings Inc.
ALXO
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor inā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.97
Price+0.51%
$0.01
1Y
Price
Market Cap
$265.089m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$88.868m
+12.6%
1y CAGR+17.8%
3y CAGR+5.8%
5y CAGREPS
-$1.65
+13.2%
1y CAGR+23.5%
3y CAGR+11.8%
5y CAGRBook Value
$151.347m
$178.328m
Assets$26.981m
Liabilities$5.217m
DebtDebt to Assets
2.9%
-0.1x
Debt to EBITDAFree Cash Flow
-$78.329m
+7.1%
1y CAGR+15.1%
3y CAGR+0.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company